A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55, EU-approved Cosentyx and US-licensed Cosentyx in Healthy Male Subjects
Latest Information Update: 15 Jul 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Celltrion
Most Recent Events
- 15 Jul 2025 New trial record